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Abstract
Type VI Secretion Systems (T6SSs) have been identified in numerous Gram-negative pathogens, but the lack of a natural
host infection model has limited analysis of T6SS contributions to infection and pathogenesis. Here, we describe disruption
of a gene within locus encoding a putative T6SS in Bordetella bronchiseptica strain RB50, a respiratory pathogen that
circulates in a broad range of mammals, including humans, domestic animals, and mice. The 26 gene locus encoding the B.
bronchiseptica T6SS contains apparent orthologs to all known core genes and possesses thirteen novel genes. By generating
an in frame deletion of clpV, which encodes a putative ATPase required for some T6SS-dependent protein secretion, we
observe that ClpV contributes to in vitro macrophage cytotoxicity while inducing several eukaryotic proteins associated with
apoptosis. Additionally, ClpV is required for induction of IL-1b, IL-6, IL-17, and IL-10 production in J774 macrophages
infected with RB50. During infections in wild type mice, we determined that ClpV contributes to altered cytokine
production, increased pathology, delayed lower respiratory tract clearance, and long term nasal cavity persistence.
Together, these results reveal a natural host infection system in which to interrogate T6SS contributions to
immunomodulation and pathogenesis.
Citation: Weyrich LS, Rolin OY, Muse SJ, Park J, Spidale N, et al. (2012) A Type VI Secretion System Encoding Locus Is Required for Bordetella bronchiseptica
Immunomodulation and Persistence In Vivo. PLoS ONE 7(10): e45892. doi:10.1371/journal.pone.0045892
Editor: Ivo G. Boneca, Institut Pasteur Paris, France
Received February 21, 2012; Accepted August 27, 2012; Published October 12, 2012
Copyright:  2012 Weyrich et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was funded by National Institutes of Health (NIH) grant GM083113 (E.T.H.). This material is based upon work supported by the National
Science Foundation Graduate Research Fellowship under Grant No. DGE 070756. The funders had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Harvill@psu.edu
. These authors contributed equally to this work.
Introduction
Highly conserved Type VI Secretion System (T6SS) gene
clusters have been recently identified in 92 different strains of
bacteria [1]. T6SS loci are disproportionately associated with
virulent strains, and multiple virulence-related phenotypes have
been attributed to the T6SS in pathogenic bacteria, including
mucosal adherence, intracellular growth within macrophages,
survival within host cells, and the delivery of bacteriolytic proteins
into competitor bacteria [1–5]. In Vibrio cholerae [6], Aeromonas
hydrophila [7], and Legionella pneumophila [8], T6SS activity enables
macrophage cytotoxicity, while T6SSs of Salmonella typhimurium and
Yersinia pseudotuberculosis facilitate HEp-2 cell invasion [9]. Abro-
gating T6SS functions is associated with reduced virulence in vivo
of Aeromonas hydrophila in a mouse model of septicemia [10],
Pseudomonas aeruginosa in neutropenic mice [11], V. cholera in infant
mice and rabbits [12,13], and Burkholderia mallei in hamsters [14].
Strikingly, disruption of the T6SS in Entero-Aggregative Escherichia
coli (EAEC) does not cause an observable loss of function in a wild
type murine infection model [15]. With the exception of A.
hydrophila, Salmonella enterica, and Francisella tularensis, many T6SS-
associated in vitro phenotypes were not observed in adult, wild type
mice [7,16,17]. Despite evidence that the T6SS enables virulence
in multiple species, many of the discrete, in vivo interactions
between the T6SS and host immunity have not yet been
determined.
This study examines the T6SS in the common respiratory
pathogen, Bordetella bronchiseptica. This Gram-negative bacterium
infects a wide range of mammals, including humans, and causes
disease severities ranging from asymptomatic carriage to fatal
pneumonia. B. bronchiseptica commonly causes kennel cough in
domesticated animals, snuffles in rabbits, and atrophic rhinitis in
swine and is considered the evolutionary progenitor-like strain of
B. pertussis and B. parapertussis, causative agents of whooping cough
in humans [18]. B. bronchiseptica also efficiently infects and causes
disease in laboratory animals, such as mice, rats, and rabbits,
providing a natural host infection model that has been used to
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reveal important interactions between bacterial virulence factors
and the host immune system in vivo [19,20].
A considerable number of specific bordetellae virulence
determinants, such as autotransporters, adhesins, and toxins,
require secretion through various machineries, such as the Type I,
Type II, Type III, Type IV, and Type V secretion systems (TnSS)
[18,21]. These secretion systems export factors that enable host
epithelium adherence [22], disable the mucociliary escalator [23],
manipulate signaling pathways in antigen presenting cells [24,25],
and block neutrophil chemokine receptors [26]. Bordetella virulence
factors, such as adenylate cyclase toxin (ACT), pertussis toxin
(PTX), fimbria, Bordetella resistance to killing protein (BrkA),
filamentous hemagglutinin (FHA), pertactin (PRN), and tracheal
colonization factor (TCF), have all been shown to require secretion
systems for export [21,27–29]. Even when many secreted factors
are unknown, abrogating secretion by these systems can result in
observable effects [24,30,31]. For example, increased expression of
the B. bronchiseptica T3SS locus correlated with hypervirulence in
vivo, and before a specific secreted effector was identified,
disruption of the T3SS was associated with decreased in vitro
cytotoxicity and in vivo pathology [32–35]. Although a locus
homologous to known T6SSs was not identified in B. pertussis, a
putative T6SS locus was identified in B. bronchiseptica and B.
parapertussis genomes, and its secreted effectors, function, and
contributions to Bordetella pathogenesis have not yet been
characterized [21,36].
To examine the role of the T6SS in Bordetella pathogenesis, we
analyzed the 26 gene locus in B. bronchiseptica strain RB50, a strain
which has been extensively characterized in various animal
models. An in-frame deletion of the gene encoding a putative
T6SS ATPase, clpV, altered interactions with macrophages in vitro,
affecting the secretion of IL-1b, IL-6, IL-10 and IL-17. The
RB50DclpV strain was also defective in cytotoxicity toward
macrophages in vitro, a phenotype previously associated with both
Adenylate Cyclase Toxin (ACT) and a Type Three Secretion
System (T3SS). Furthermore, mutation of hcp, a structural
component of other T6SSs, and a clpV mutation in another
hypervirulent B. bronchiseptica lineage also resulted in a loss of
cytotoxicity. During infection in wild type mice, clpV was required
to induce significant pathology in the lungs. RB50DclpV was also
rapidly cleared from the lower respiratory tract and deficient in
nasal cavity persistence. Together, these data indicate that the
T6SS plays an essential role in B. bronchiseptica pathogenesis and




This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care and Use
Committee at The Pennsylvania State University at University
Park, PA (#31297 Bordetella-host Interaction). All animals were
anesthetized using isoflourane or euthanized using carbon dioxide
inhalation to minimize animal suffering.
Comparative protein sequence analysis
Based on Boyer et al. analysis, there are 35 genes (BB0787–
BB0821) in the B. bronchiseptica T6SS locus [1]. However, six genes
(BB0787–BB0792) upstream of BB0793 were annotated as
possible T2SS locus in RB50, and there are only three predicted
operons (BB0793–BB0810, BB0811–BB0812, and BB0813–
BB0818) within this locus based on OperonDB (http://
operondb.cbcb.umd.edu/cgi-bin/operondb/pairs.
cgi?genome_id = 120). Thus, we have defined the T6SS locus with
26 genes (BB0793–BB0818). The DNA and protein sequences
corresponding to all the genes present in T6SS locus of B.
bronchiseptica strain RB50 were obtained online (http://www.ncbi.
nlm.nih.gov); the orthologous genes in P. aeruginosa, S. enterica, and
V. cholerae were located via KEGG ortholog database (http://www.
genome.jp/kegg/genes.html). The amino acid sequence similarity
was determined by comparing RB50 genes to orthologous genes in
P. aeruginosa, S. enterica, and V. cholerae using the online NCBI
protein BLAST search (http://www.ncbi.nlm.nih.gov/BLAST).
Bacterial strains and growth
B. bronchiseptica strain RB50 and strain 1289 have been described
elsewhere [35,37]. Bacteria were maintained on Bordet-Gengou
agar (Difco) supplemented with 10% sheep blood (Hema
Resources) with 20 mg/ml streptomycin (Sigma). Bacteria were
grown in liquid culture to mid-log phase while shaking in Stainer-
Scholte (SS) broth [38] overnight at 37uC.
Construction of RB50DclpV and 1289DclpV strains
The RB50DclpV strain was constructed using an allelic exchange
strategy as previously described [35]. The first three codons of clpV
(BB0810) and the 630 base pairs (bp) upstream were amplified via
PCR using primers flanked with EcoRI on the 59 end and HindIII
on the 39 end (Table S1, 59F and 59R). The last eight codons of
clpV and the 432 bp downstream were amplified via PCR using
primers flanked with HindIII on the 59 end and EcoRI on the 39
end (Table S1, 39F and 39R). These fragments were PCR purified
(Qiagen, Valencia, CA), BamHI digested (New England Biolabs),
gel purified (Qiagen, Valencia, CA), and ligated overnight at 4uC
(New England Biolabs), and amplified with the 59 F and 39 R
primers as described above. The 1,280 bp knock-out construct was
then ligated into the TOPO-TA vector, transformed into Mach1
DH5a cells (Invitrogen), and verified by sequencing. The 1280-bp
construct was digested from TOPO-TA, gel purified, and ligated
overnight into the EcoRI-digested pSS4245, a Bordetella allelic
exchange vector (courtesy of S. Stibitz). Triparental mating with
DH5a harboring pSS4545 DclpV, DH5a containing pSS1827, and
B. bronchiseptica strain grown under Bvg2 conditions by growth on
BG plus 50 mM MgSO4 was done for 4 hrs on a BG-10 mM
MgCl2-50 mM MgSO4 plate at 37uC. Then, B. bronchiseptica
containing pSS4245 DclpV was positively selected by growth on
BG-streptomycin-kanamycin-50 mM MgSO4 plates and incubat-
ed for 2 days at 37uC; this step was repeated to ensure purity. The
resulting colonies were streaked onto BG plates and incubated for
2 days at 37uC, which resulted in colonies lacking pSS4245 and
containing either the wild-type or knockout gene. Colonies were
then screened for the presence of either the wild-type or knockout
gene by using screening primers (Table S1) which detected either
the wild-type clpV (2,003 bp) or the DclpV deletion (1,280 bp) with
PCR. The absence of pSS4245 was confirmed by growth on BG-
streptomycin plates and lack of growth on BG-kanamycin plates.
qRT-PCR
Quantitative reverse transcription PCR (qRT-PCR) was pre-
formed as previously described [35,39,40]. Briefly, bacteria at an
OD600 0.2 were subcultured into four independent five mL
cultures until OD600 reached 0.8; 10
8 cells were immediately
pelleted by centrifugation at 4uC 8,000 RPM for five minutes.
Total RNA was extracted with Trizol (Invitrogen), treated with
RNase-free DNase I (Invitrogen), and purified using RNeasy
columns (Qiagen) according to the instructions of the manufac-
T6SS Associated Virulence by B. bronchiseptica
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turer. One microgram of RNA from each biological replicate was
reverse transcribed using 300 ng of random oligonucleotide
hexamers and SuperScript III RTase (Invitrogen). The resulting
cDNA was then diluted 1:100, and 1 mL aliquots were used for
qRT-PCR. 300 nM of primers (Table S1B) designed using IDT
DNA software (http://www.idtdna.com) were used in conjunction
with 26 SYBR green PCR master mix (Applied Biosystems).
Control samples of reaction mixtures excluding reverse transcrip-
tase were included to confirm the absence of DNA contamination;
amplification of the 16S RNA amplicon was used as an internal
qRT-PCR control. Dissociation curve analysis was preformed to
confirm sample homogeneity. Threshold fluorescence was estab-
lished within the geometric phase of exponential amplification,
and the cycle threshold (CT) was determined for each sample. The
CT from each replicate was averaged, and the 16S RNA amplicon
was used as internal control for data normalization. The change in
transcript level was determined using the relative quantitative CT
method (DDCT) [41]. All primers used in qRT-PCR analysis can
be found in Table S1B.
Cytotoxicity assay
Cytotoxicity assays were preformed as previously described
[34,35,42]. Briefly, murine macrophage J774A.1 cells (ATCC)
were cultured in Dulbecco’s modified Eagle’s medium (DMEM,
Difco) supplemented with 10% fetal bovine serum, 1% penicillin-
streptomycin, 1% nonessential amino acids, and 1% sodium
pyruvate. The cells were grown to 85% confluency in 5% CO2 in
96-well plates (Greiner Bio-One) at 37uC. DMEM was then
replaced with RPMI medium lacking phenol red with 5% fetal
bovine serum, 1% L-glutamine, 1% nonessential amino acids, and
1% sodium pyruvate at least one hour prior. Bacteria diluted in
RPMI at multiplicities of infection (MOI) of 0.1, 1, and 10 were
centrifuged onto the macrophages at 3006g for 5 minutes and
incubated in 5% CO2 at 37uC for 2, 4, and 6 hours. The cell
culture supernatants were collected, and lactate dehydrogenase
(LDH) release, a measure of cytotoxicity, was analyzed using a
Cytotox96 kit (Promega) according to the instructions of the
manufacturer.
Protein Extraction and 2D Gel Electrophoresis
RAW 264.7 cells obtained from ATCC were grown in DMEM
supplemented with 10% FBS in a 5% CO2 incubator at 37uC.
The cells were grown in a monolayer in 6 well cell culture plates
(70% confluency), and serum free media was applied 3 hours
before the beginning of the assay. Six wells of monocyte cells were
treated with media alone, B. bronchiseptica strain RB50, or
RB50DclpV at an MOI of 10, centrifuged at 2506g for 5 minutes,
and incubated at 37uC and 5% CO2 for 2 hours. Cellular protein
was extracted using previously established methods [43]. Briefly,
the supernatant was removed from each well, and the cultured
cells were washed twice in phosphate-buffered saline (PBS). The
cells were then harvested by scraping into 3 mL cold buffer
containing 50 mM Tris pH 8.6, 10 mM EDTA, 65 mM DTT,
protease-inhibitor cocktail (Pierce), 2000 U/mL DNase I (Am-
bion) and 2.5 mg/mL RNase A (Qiagen), and the cellular
suspensions were pooled. The cells were lysed using a homoge-
nizer at 4uC and centrifuged at 10006g to remove membranes.
The protein concentration was determined using the Pierce
660nm assay (Thermo Scientific), as per manufacturer’s instruc-
tions. Two-dimensional (2D) electrophoresis was performed using
the Ready-Prep 2D Starter Kit (Bio-Rad) using IPG strips with pH
range 3–10 (Bio-Rad) for the first dimension and Criterion 12.5%
Tris HCL precast gels (Bio-Rad). 500 mg of protein were loaded
for each sample, and the gels were stained with Gelcode Blue
reagent (Pierce). The gels were analyzed using PDQuest software
(Biorad). Protein spots were excised and trypsin digested for
analysis using nano-LC MS/MS (Waters QTOF Premier). The
proteins were identified using MASCOT software (Matrix).
Intracellular staining
Intracellular staining of J774 murine macrophages was
performed as previously described [44]. Briefly, cells grown on
coverslips were washing three times with PBS and fixed in 4%
paraformaldehyde in phosphate-buffered saline buffer (PBS)
(Omnipur) for ten minutes. Cells were then against washed three
times with PBS and blocked with 3% bovine serum albumin in
PBS for 30 minutes. The primary antibody, Annexin V-FITC (BD
Pharmingen), was diluted in 3% BSA and PBS and incubated with
the cells for 1 hour at room temperature. After three washes in
PBS, the cells were stained with DAPI/PBS for 10 minutes at
room temperature. Cells were then mounted onto glass slides in
Vectashield (Vector Laboratories, Inc., Burlingame, CA) and
examined using a materials microscope (Olympus BX61) at the
Cytometry Core Facility at University Park, PA. All imaged were
saved as TIFF files and processed in Microsoft Powerpoint.
Cytokine detection
Cytokine analysis was preformed as previously described
[45,46]. Briefly, cell culture supernatants were collected from
J774 macrophages that were stimulated with RB50 or RB50DclpV
at an MOI of 0.1 for 2, 4, 6, and 24 hours or murine lung
homogenates that were used for bacterial quantification and
frozen at 280uC until assayed were collected. Interleukin-1b (IL-
1b), interleukin-6 (IL-6), interleukin-10 (IL-10), interleukin-17 (IL-
17), Interferon-c (IFN-c), and tumor necrosis factor a (TNFa)
concentrations were determined via ELISA in accordance with the
supplier’s protocols (R&D Systems).
Animal experiments
Wild type C57BL/6 mice were obtained from Jackson
Laboratories, Bar Harbor, ME. Mice were bred and maintained
at a specific pathogen-free facility at The Pennsylvania State
University, University Park, PA, and all experiments were carried
out in accordance with all institutional guidelines. All animal
experiments were done as previously described [20,35,47]. Briefly,
the number of bacterial colony forming units in liquid cultures was
calculated based on the optical density measured by absorbance of
light at 600 nm. Bacteria were then diluted to 107 CFU/ml in
sterile PBS. Inocula were confirmed by plating dilutions on BG
agar and counting the resulting colonies after two days of growth
at 37uC. For inoculation, mice were sedated with 5% isoflurane
(IsoFlo, Abbott Laboratories) in oxygen and inoculated by gently
pipetteing 50 ml PBS containing the indicated CFU of bacteria
onto the external nares. For quantification of bacterial numbers,
mice were euthanized with CO2 inhalation and the indicated
organs were excised. Tissues were homogenized in PBS, serially
diluted and plated onto BG agar plates with 20 mg/mL
streptomycin, and colonies were counted after 2 days of growth
at 37uC. Survival curves were generated as previously described
[35]. Mice were observed over a 28 day period; any mouse
exhibiting lethal bordetellosis, indicated by ruffled fur, labored
breathing, and diminished responsiveness, was euthanized imme-
diately to prevent unnecessary suffering [20,48].
Lung pathology
Three days following inoculation with either RB50 or
RB50DclpV, the mice were euthanized and the trachea and lungs
T6SS Associated Virulence by B. bronchiseptica
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were inflated with 1.5 ml of 10% formalin in PBS. The tissues
were processed and stained with hematoxylin and eosin (H&E) at
the Animal Diagnostic Laboratory at The Pennsylvania State
University, in University Park, PA. Sections were analyzed and
scored on a qualitative scale as previously described [48]. An
assessment of microscopic lesions was made by a by one of the
authors (M. J. Kennett) experienced in rodent pathology and
blinded to experimental treatment. Descriptive evaluations of the
lesions were recorded, and lung lesions were graded by using a
scale of 0 to 5. Sections with no lesions and no inflammation were
given a score of 0, a score of 1 indicated slight inflammation with
few or scattered lesions and fewer than 10% of lung fields affected,
a score of 2 indicated mild lesions with 10 to 20% of lung fields
affected, a score of 3 indicated moderate lesions with 20 to 30% of
the lung fields affected, and those given a score of 4 were
characterized by extensive lesions, marked inflammation, and 31
to 50% of the lung was affected. A score of 5 indicated there were
extensive lesions with .50% of the lung fields affected.
Results
T6SS locus in Bordetella bronchiseptica strain RB50
In 2008, Bingle et al. used comparative sequence analysis to first
identify the T6SS associated genes present in the published
genome of B. bronchiseptica [36]. Four of these proteins in B.
bronchiseptica shared homology to proteins that have been dubbed
the ‘core components’ of the T6SS machinery: ClpV, IcmF, Hcp,
and VgrG [1,36]. In this study, we characterize a contiguous 26
gene locus in B. bronchiseptica strain RB50 predicted to encode
proteins sharing high amino acid sequence similarity with highly
conserved T6SS proteins found in V. cholerae, S. enterica and P.
aeruginosa (Figure 1). We have retained the names of the T6SS
‘core component’ genes, while naming the unique T6SS genes of
Bordetella tssA-V, representing ‘‘type six secretion’’ and maintain-
ing nomenclature put forth by Shalom, et al (Figure 1) [49].
Amino acid sequence motif analysis of the predicted protein
ClpV, a putative AAA+ ATPase, revealed two ATP binding sites
with Walker A and B motifs [50] (J. Park and E.T. Harvill,
unpublished data), suggesting that it may enable effector molecule
binding or provide energy for protein translocation, as observed
in V. cholerae, P. aeruginosa, E. coli, and other bacteria [36,51].
Recently, Basler et al. indicated that clpV was not essential for all
of the T6SS-dependent bacteriocidal activities in V. cholerae and
may be required for the retraction of the contractile sheath-like
structure of the T6SS [52,53], indicating that ClpV may
contribute to cellular activities in addition to its predicted
ATPase functions. The predicted IcmF protein identified in
bordetellae is similar to the IcmF- and IcmH-like proteins found
in the T4SS. Yeast two hybrid assays in Edwardsiella tarda suggest
that IcmF- and IcmH-like proteins may form a transport
apparatus and act synergistically in translocating substrates
[54]. A gene sharing 20% amino acid sequence identity to the
Hcp encoding gene in V. cholerae and 40% identity with that of P.
aeruginosa was identified in B. bronchiseptica. Hcp may function as
an effector and/or assemble into a hexameric ring structure that
forms a channel or pilus for conduction of other effectors through
the cell membrane, which has been shown to be essential for
T6SS mediated virulence in Vibrio and Pseudomonas [55]. A
homolog of vgrG, currently annotated as vrgS, was identified in B.
bronchiseptica, possessing 34% and 41% sequence identity with V.
cholerae and P. aeruginosa vgrG genes, respectively, and contains the
GP5 region predicted to form the base of the needle apparatus.
VgrG of V. cholerae contains regions of homology to the actin
cross-linking domain of an RtxA toxin [56], and more recently
has been shown to share homology with the gp27 of T4
bacteriophage, which forms part of a tail spike apparatus for
membrane penetration [57,58]. Both Hcp and VgrG are found in
the secretomes of most bacteria possessing a functional T6SS,
even though they lack an export signal peptide [4,6,36]. These
same four ‘core’ components of the T6SS machinery were also
identified in B. parapertussis strain 12822; however, further DNA
sequence analysis of this locus identified frameshift mutations in
upstream genes and a pseudogene that replaced vgrG (J. Park and
E.T. Harvill, unpublished data), suggesting it may be either
defective or functionally different from the locus found in B.
bronchiseptica. No T6SS genes were found in the sequenced
genome of B. pertussis strain Tohoma I, indicating that this locus
may have been lost through genome degradation in the course of
B. pertussis evolution [59].
Deletion of clpV from B. bronchiseptica strain RB50
ClpV has been shown to be required for translocation of T6SS
effector proteins essential for virulence in V. cholerae, P. aeruginosa,
and E. coli [3,4,60]. To investigate the role of T6SS in B.
bronchiseptica pathogenesis, we constructed an in-frame deletion of
clpV (BB0810) in the genome of B. bronchiseptica strain RB50
(RB50DclpV) by utilizing the bordetellae allelic exchange vector
pSS4245 [35]. The wild type gene produced a 2,003 bp PCR
product, whereas the clpV mutant region resulted in a product of
1,280 bp, as expected (Figure 2A). Following deletion of clpV,
expression of the four core T6SS proteins, icmF, hcp, vgrG, and clpV
in RB50DclpV was compared with expression in the parental strain
by qRT-PCR. Expression of icmF, hcp, and vgrG in the mutant
strain remained comparable to that of RB50 while clpV expression
was reduced to background levels, suggesting that this gene has
been effectively disrupted without altering the expression of
neighboring genes (Figure 2B). The growth rate of RB50DclpV
in SS broth at 37uC was not different from that of parental strain
RB50 (data not shown), further suggesting that clpV was
successfully disrupted without causing additional defects.
T6SS contributes to cytotoxicity of murine macrophages
In other bacterial systems, the T6SS has been found to mediate
interactions between bacteria and phagocytic cells, including
protection against amoeba predation, enhanced intracellular
survival within macrophages, and the ability to directly kill
macrophages in vitro [4,6,7,16]. Additionally, because B. bronchi-
septica is known to be highly cytotoxic to cultured macrophages, we
hypothesized that the T6SS may play a role in cytotoxicity. Using
a lactate dehydrogenase (LDH) release assay, we measured the
cytotoxic effects of B. bronchiseptica on murine macrophages. When
macrophages were infected with either RB50 at a MOI of 1, we
observed increasing levels of cytotoxicity over the first 6 hours of
incubation (Figure 3A). By six hours, 71% of macrophages were
lysed by RB50, as previously described [35,61,62]. Minimal
cytotoxicity was observed in macrophages exposed to RB50DclpV
at any point throughout the 6 hour incubation (Figure 3A).
Because complementation by plasmid expression of clpV was
unsuccessful after multiple attempts, clpV was deleted from RB50
three times, independently, with identical effects on cytotoxicity
(data not shown). Further, we deleted clpV from another wild-type
B. bronchiseptica isolate, strain 1289, known to exhibit hyperviru-
lence and increased cytotoxicity associated with T3SS overex-
pression. As expected, wild type 1289 induced 92% cytotoxicity
after six hours incubation, more than the 71% induced by RB50
(Figure 3A). Similar to RB50DclpV, the clpV mutant of 1289
induced minimal cytotoxicity at all time points, suggesting that
ClpV is required for macrophage killing in multiple B. bronchiseptica
T6SS Associated Virulence by B. bronchiseptica
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strains. A mutant lacking the gene encoding Hcp, which encodes a
putative T6SS structural component, was additionally constructed
in our laboratory (S. J. Muse and E. T. Harvill, unpublished data)
and also failed to induce cytotoxicity (Figure 3B), further
supporting a role for the B. bronchiseptica T6SS in macrophage
killing.
To examine the ClpV-mediated mechanism of LDH release,
J774 cells were stained for the presence of Annexin V after being
incubated with either strain RB50 or RB50DclpV at an MOI of
100 for 2 hours. Significantly more Annexin V positive macro-
phages were observed when cells were incubated with RB50
compared to RB50DclpV (Figure 3C). Additionally, RB50DclpV
stimulated small Annexin V puncta near the membrane without
stimulating full Annexin V membrane staining. Together, these
results suggest that the T6SS contributes to the apoptotic death of
macrophages in vitro.
Macrophage proteome changes in response to T6SS
To investigate which cell signaling pathways are involved in
T6SS-mediated macrophage cell death, we analyzed the proteome
of murine macrophages exposed to either RB50 or RB50DclpV.
Murine J774 macrophages were stimulated with either RB50 or
RB50DclpV at an MOI of 10 for 2 hours, lysed, and analyzed by
two dimensional (2D) gel electrophoresis. This approach enables
identification of bacterial proteins secreted into eukaryotic cells in
a contact dependent manner [4]. This approach also enables
detection of proteins that are differentially produced by macro-
phages in response to a functional T6SS. A total of 431 different
proteins were visualized by 2D gel electrophoresis, and 283
proteins differed between RB50 or RB50DclpV infected macro-
phages (Figure S1 and S2). The six most prominent proteins that
were only observed in RB50 infected cells (proteins a–e) were
identified via mass spectrometry as an initial analysis to investigate
how murine macrophages are affected by the B. bronchiseptica T6SS
Figure 1. A genetic comparison of B. bronchiseptica T6SS locus to known T6SS loci. The T6SS locus from B. bronchiseptica is compared to
loci in P. aeruginosa, S. enterica, and V. cholerae. Homologous genes are indicated with the same color, while genes with no homologues are indicated
with white color. The numbers in the arrows indicate the percentages of amino acid sequence similarity compared to B. bronchiseptica. The length of
arrows is relative to the length of the gene. * Indicates the gene targeted for deletion in B. bronchiseptica and its homologues.
doi:10.1371/journal.pone.0045892.g001
Figure 2. Confirmation of RB50DclpV construction by PCR and
RT-PCR analysis. A. PCR analysis of clpV in RB50 (left) and RB50DclpV
(right). Size markers are designated on the left. B. RT-PCR analysis of
relative expression of vgrG, hcp, clpV, icmF, bvgS, and fhaB in RB50DclpV
relative to RB50 expressed as mean 6 standard deviation. Each gene
was normalized to the expression of 16S RNA.
doi:10.1371/journal.pone.0045892.g002
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(Figure 4A). Murine macrophage proteins identified included
pyruvate kinase isoxyme M1 M2, transcription factor E2F7,
isocitrate dehydrogenase NADP Fragment, voltage dependent
anion selective channel protein 2, and guanine nucleotide binding
protein subunit beta 2 like 1. NADH-quinone oxidoreductase
subunit C was the only bacterial protein identified. Together, this
data suggests that deletion of clpV changes the macrophage cellular
response produced during infection in vitro.
T6SS stimulates IL-1b and IL-6 production in vivo
To assess the effects of clpV deletion on macrophage cytokine
production, cultured macrophages were exposed to either RB50 or
RB50DclpV at an MOI of 0.1 for 24 hours, and IL-1b, IL-6, IL-10,
IL-17, IFN-c, and TNFa were analyzed because these cytokines
are known to contribute to host immunity or pathogenesis [45,48].
No changes were observed in TNFa production at 2 hours post
inoculation (data not shown). By 24 hours of stimulation with
Figure 3. T6SS mediates cytotoxicity in murine macrophages. A–B. LDH release assay monitoring cytotoxicity of J774 murine macrophages at
an MOI of 1 for 2, 4, and 6 hour incubations with RB50, RB50DclpV, 1289, or 1289DclpV (A), and the same assay conducted independently to compare
RB50, RB50DclpV, and RB50Dhcp induced cytotoxicity after a 4 hour incubation (B). C. J774 macrophages stained with Annexin V (green) and DAPI
(blue) after incubation with RB50, RB50DclpV, or media alone for three hours. * denotes p value,0.05.
doi:10.1371/journal.pone.0045892.g003
Figure 4. T6SS induces changes in the macrophage proteome during in vitro infection. A. Two dimensional gel electrophoresis was
performed on whole cell extract from macrophages infected with either RB50 or RB50DclpV at an MOI of 10 for 2 hours. A section of the 2D gel image
is shown, and the entire 2D gel image can be seen in Figure S1. The six most prominent proteins, which were also selected for identification by mass
spectrometry, are circled in black and labeled (a–e). Top hits from MASCOT correlating to each identified protein (a–e) are listed below the images.
doi:10.1371/journal.pone.0045892.g004
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either wild type or the mutant bacteria, similar amounts of TNFa
were produced (Figure 5A). In contrast, macrophages exposed to
RB50 produced more IL-6 and IL-1b than those exposed to
RB50DclpV (Figure 5B–C), suggesting that the T6SS may
stimulate IL-6 and IL-1b production independently of TNFa
induction. Not surprisingly, IL-17, known to be induced by IL-1b,
was also more up-regulated in RB50 stimulated macrophages
compared to macrophages stimulated by the clpV mutant
(Figure 5D). Stimulation of IL-6, IL-1b, and IL-17, independent
of ClpV-mediated TNFa production, suggests that the T6SS may
play a role in recruiting immune cells to the site of infection. We
also investigated production of the anti-inflammatory cytokine, IL-
10, and its antagonist Th1 cytokine, IFN-c. We observed that wild
type bacteria induced more IL-10 production than the clpV mutant
and very low levels of IFN-c, suggesting that a mutant lacking clpV
may affect cell recruitment by altering IL-10 production
(Figure 5E–F). Together, this data suggests that the T6SS may
affect cytokine production that regulates inflammation initiation
and cell recruitment, and may thereby affect downstream adaptive
immune response pathways.
T6SS is required for persistence in the murine respiratory
tract
To determine whether ClpV-dependent effects on cytokine
production in vitro contribute to in vivo colonization and persistence
of Bordetella, we used a well established murine model of infection
[37,63]. We inoculated C57BL/6 mice with 56105 CFU of B.
bronchiseptica strain RB50 or RB50DclpV, and bacterial numbers
were determined in the nasal cavity, trachea, and lungs at 0, 3, 7,
14, 28 and 49 days post-inoculation (Figures 6A–C). RB50DclpV
colonized the respiratory tract similarly to RB50 for the first three
days post-inoculation. However, by day 7 RB50DclpV numbers in
the lungs were one tenth that of RB50 (Figure 6C). Compared to
wild type, fewer RB50DclpV bacteria were reported in the trachea
by day 14, and by day 28 numbers of the mutant were lower in the
nasal cavity (Figures 6A and 6B). The bacterial load of both
mutant and wild type declined over time in the nasal cavity,
trachea, and lungs; however, RB50DclpV was cleared from the
trachea and lungs 28 days post-inoculation, while significant
numbers of RB50 could still be detected in the lungs 49 days post-
inoculation. Wild-type B. bronchiseptica is known to persist
indefinitely (.150 days) in the nasal cavities of laboratory mice
at levels greater than 103 CFU [64]. While RB50DclpV was still
present in the nasal cavity after 49 days, it was reduced to
approximately 102 CFU (Figure 6A). Together, these data suggest
that the T6SS contributes to the ability of B. bronchiseptica to persist
in the murine respiratory tract.
T6SS mediates increased pathology and cell recruitment
in vivo
When mice were dissected three days following infection with
RB50, their lungs were visibly inflamed and erythematous. In
contrast, the lungs of mice infected with RB50DclpV appeared
healthy (data not shown). We hypothesized that although bacterial
loads recovered from each group were comparable at this time
point, T6SS activity was causing enhanced leukocyte recruitment
into the lungs and increased tissue damage and host cell necrosis.
Histological analysis of lungs stained with H&E revealed
significantly attenuated inflammatory pathology in mice infected
with RB50DclpV (2.3 score) relative to those infected with RB50
(3.7 score) (Figure 6D). In the lungs of RB50 infected mice, we
observed a robust accumulation of polymorphonuclear cells
(PMNs) cuffing the perivascular spaces, infiltrating into the
connective tissue underlying the respiratory epithelium of the
bronchioles, and collecting within alveolar spaces. In comparison,
lungs from mice infected with RB50DclpV had visibly reduced
cellular infiltration into perivascular spaces and very little infiltrate
in the alveolar spaces. Despite significantly higher pathology
scores, a similar amount of necrotic cell death was observed in
both the RB50 and RB50DclpV infected lungs (Figure 6D). The
LD50 of wild type RB50 in C57BL/6 mice is approximately
106.3 CFU, and fatality from this dose occurs within three days of
inoculation [35]. C57BL/6 mice inoculated with up to 108.1 CFU
of RB50DclpV survived for at least 90 days, indicating the virulence
of B. bronchiseptica requires this T6SS gene (data not shown). These
data suggest that the T6SS contributes to B. bronchiseptica-mediated
pathology and decreases the mean lethal dose of B. bronchiseptica
strain RB50.
T6SS modulates a Th1 immune response
We observed decreased cytokine production in vitro and
decreased cell recruitment in vivo. Therefore, we measured
cytokines at the infection site to determine whether a functional
T6SS alters cytokine production in ways that might cause skewing
Figure 5. ClpV contributes to cytokine production in vitro. A–C.
Supernatants from infected murine macrophages were recovered after
24 hours at an MOI of 0.1 of RB50 (dark bars) or RB50DclpV (light bars)
and assayed for TNFa (A), IL-6 (B), IL-1b (C), IL-17 (D), IL-10 (E) and IFN-c
(F). * denotes p value,0.05.
doi:10.1371/journal.pone.0045892.g005
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of the T helper cytokine response profile. We directly assayed lung
homogenates from day 7 and 28 post-inoculation for the presence
of cytokines. On day 7 post-inoculation, we found that mice
infected with RB50DclpV had lower levels of cytokines associated
with Th17 responses, IL-6 and IL-17, and significantly higher
levels of the Th1 cytokine, IFN-c, when compared to RB50
infected mice (Figure 7A–C). However, these differences were not
observed in lung homogenates from day 28 post-inoculation, and
no differences were observed between RB50 or RB50DclpV
infection in TNFa, IL-1b, and IL-10 at either time point (data
not shown). Th1 responses have been shown to be critical for
immune mediated clearance of B. bronchiseptica, while Th17 cells
have been shown to contribute to the clearance of closely related
pathogen, B. pertussis [65]. These findings suggest that the T6SS
may delay immune mediated clearance by shifting the immune
reaction to a Th17 response and preventing the development of
critical Th1 responses.
Discussion
This work represents the first investigation of T6SS function in
the genus Bordetella and describes a robust natural host infection
model in which the subtleties of complex immune interactions with
the host can be dissected. As with multiple other pathogens, we
find that mutation of clpV affects macrophages cytotoxicity in vitro
and that ClpV-dependent interactions with macrophages result in
proteomic changes consistent with apoptotic responses. Addition-
ally, we observed that ClpV contributes to IL-1b, IL-6, IL-10, and
IL-17 production in murine macrophages in vitro, and using
natural host infection, confirmed that changes in IL-17 and IL-6
production in vivo are ClpV-dependent. Enhanced immunopathol-
ogy and respiratory tract persistence were also found to be ClpV-
mediated, potentially by affecting the development of an effective
Th1 immune response essential for the clearance of this pathogen.
Our results suggest that clpV, a gene linked to T6SS function, is a
novel virulence factor that significantly contributes to the
pathology and persistence of the respiratory pathogen B.
bronchiseptica.
Numerous Gram-negative pathogens, such as Vibrio choleraee [6],
Aeromonas hydrophila [7], Legionella pneumophila [8], Salmonella
typhimurium, and Yersinia pseudotuberculosis [66] possess a T6SS that
contributes to virulence during in vitro infections. This study shows
that the B. bronchiseptica T6SS gene clpV is required for macrophage
cytotoxicity and identifies proteomic changes associated with
T6SS-mediated cellular apoptosis, including proteins associated
with intracellular bacterial survival (pyruvate kinase isozymes M1/
M2) [67], intracellular signaling (voltage dependent anion
selection channel) [68], structural mimicry (guanine nucleotide
binding protein subunit beta 2) [69], and apoptosis (voltage
dependent anion selection channel, transcription factor E2F7 and
isocitrate dehydrogenase NADP fragment) [70–72]. Although the
E2F family broadly contributes to eukaryotic cell cycle regulation,
disregulation of E2F7 and E2F8 can lead to apoptosis in an E2F1-
dependent manner [70]. Additionally, the B. bronchiseptica T6SS
could be affecting host cell by targeting GTPases, as recently
observed in Burkholderia cenocepacia [73]. It is currently unclear if the
eukaryotic proteins identified here are directly controlled by
bacterial factors or whether they are transcribed from downstream
Figure 6. ClpV mediates pathology and persistence in vivo. A–C. Colonization of RB50 verses RB50DclpV in C57BL/6 mice at an inoculation
dose of 56105 CFU in 50 mL in the nasal cavity (A), trachea (B), and lung (C). D. Representative H&E lung sections from C57BL/6 mice on day 3 post-
inoculation and their average pathology scores.
doi:10.1371/journal.pone.0045892.g006
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effects. The only bacterial protein identified in macrophages
following RB50 infection was a NADH-quinone oxidoreductase
(NQO) subunit C. In other Gram-negative pathogens, a six
subunit complex including an NQO is used to transport sodium,
catalyzing electron transfer from NADH to quinone [74–76].
Pathogens, such as Helicobacter pylori, have been shown to require
similar reductases to withstand oxidative stress while inside
phagocytic cells [77]. Alternatively, there is speculation that
deregulation of NADH may be involved in eukaryotic pro-
grammed cell death, suggesting a pathogenic mechanism for this
protein [78,79]. Further research examining these discrete protein
interactions will better elucidate the specific T6SS pathogenesis
mechanisms.
It is likely that interactions between the B. bronchiseptica T6SS
and macrophages mediate critical activities very early in the course
of infection. Within the first three days of RB50 infection, although
the colonization burden of mutant and wild type are equal, there is
apparent T6SS-dependent immune-pathology and cell recruit-
ment. Both in vitro and in vivo, ClpV contributed to IL-1b, IL-6,
and IL-17 production, potentially explaining the heightened
cellular recruitment to the lungs. Thus, increased lung leukocytes
recruitment in mice infected with RB50 might be predicted to lead
to more rapid clearance of RB50; however, reduced numbers of
RB50DclpV were recovered from lungs as early as 7 days post-
inoculation. This increased immunopathology correlates with
lower in vivo production of T-helper 1 (Th1) cytokines, such as
IFN-c. Antibody production and Th1 responses have been shown
to be essential for B. bronchiseptica clearance in vivo, and it has been
hypothesized that B. bronchiseptica evolved to stimulate IL-10
production to evade clearance [80,81]. RB50DclpV stimulates a
robust Th1 response, which likely contributes to its increased
clearance from the lower respiratory tract. The exact mechanisms
behind B. bronchiseptica-induced pathology remain unclear, al-
though this could be attributed to a T6SS mediated cytotoxicity
toward macrophages and a subsequent inflammatory response.
Although not fully understood, heightened immune-pathology and
increased bacteria numbers may enable bacteria to cause disease
symptoms, such as coughing that may enhance transmission.
Alternatively, localized pathology may facilitate initial colonization
by inducing inflammation that disrupts mucociliary clearance
mechanisms or resident host microflora.
B. bronchiseptica has previously been observed to persist
indefinitely in the nasal cavity of experimental mice [35,63,82];
however the clpV mutant persists at much lower levels. It is unclear
whether the T6SS enables long-term persistence at higher
numbers in the nasal cavity by modulating key early immune
interactions that subvert productive adaptive immune responses or
whether T6SS mediates ongoing resistance to opsonophagocytic
clearance. Recent work showed that P. aeuroginosa toxin, Tse2, part
of a toxin-immunity system secreted through the T6SS, mediates
killing of other prokaryotic organisms, but not eukaryotic
organisms [58]. Since then, bacteriocidal activity has also been
observed in Vibrio and Serratia species [52,83]. Although we have
not been able to identify any obvious Tse2 homologs in the B.
bronchiseptica genome to date, the T6SS may mediate protection or
confer an advantage over host nasal microflora, preventing its
displacement by competitor species. Interestingly, the Mekalanos
laboratory recently determined that clpV is required V. cholerae
virulence against amoebae but is not as important for T6SS-
dependent bacterial killing, suggesting that ClpV may have
multiple functions that contribute to persistence in the host
[52,53,88].
Of the three classic Bordetella strains that have been sequenced,
B. bronchiseptica strain RB50, B. parapertussis strain 12822 and B.
pertussis strain Tahoma I, RB50 is the only strain whose T6SS is
predicted to be functional. Previous work has shown that RB50 is
also the only one of these strains known to be cytotoxic to
macrophages; B. pertussis and B. parapertussis have been shown to be
non-cytotoxic for up to six hours in vitro [21]. Strikingly,
RB50DclpV cytotoxicity is similar to that of B. pertussis and B.
parapertussis. Although Bordetella cytotoxicity has been attributed to
ACT and the T3SS, the loss of T6SS function may explain why B.
pertussis and B. parapertussis strains do not kill macrophages even
though they express ACT and, in some cases, have a functional
T3SS [24,84,85]. Surprisingly, RB50DclpV, which would be
expected to retain T3SS-mediated cytotoxicity, killed less than
10% of macrophages even after six hours at an MOI of 1,
suggesting that the T3SS and T6SS may have cooperative or
synergistic effects. In B. bronchiseptica, there is significant overlap in
Figure 7. In vivo IFN-c production is ClpV dependent. A–C.
Cytokines recovered from lungs of mice infected with RB50 (dark bars)
or RB50DclpV (light bars) for IL-6 (A), IL-17 (B), and IFN-c (C) on days 7
and 28 post-inoculation. * denotes p value,0.05.
doi:10.1371/journal.pone.0045892.g007
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the phenotypes of T3SS and T6SS mutants; both mutants display
overall decreased pathology, shortened duration of colonization,
and attenuated virulence in vivo [32,34,86,87]. However, only the
T6SS appears to be required for IL-6 production and nasal cavity
persistence. Interestingly, the B. bronchiseptica T3SS is known to be
BvgAS regulated, while microarray data from T. Nicholson et al.
indicate that the T6SS is not regulated by this master regulatory
system [40], suggesting that these secretion systems may be
expressed and/or required under different circumstances. Nota-
bly, the T3SS and T6SS have been shown to be expressed at
alternate times during Pseudomonas and Salmonella infection
[10,16,60]. Further work is necessary to understand the interac-
tions between these secretion systems and how they independently
and cooperatively affect the infection process.
Supporting Information
Table S1 Primer sets for the deletion and confirmation
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